Ofatumumab - Biologic Drug Details

Summary for ofatumumab

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ofatumumab

Recent Clinical Trials for ofatumumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Mario Negri Institute for Pharmacological Research	PHASE2
Novartis Pharmaceuticals	PHASE4
The First People's Hospital of Changzhou	PHASE3

See all ofatumumab clinical trials

Pharmacology for ofatumumab

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ofatumumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ofatumumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,065,011	2035-05-20	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,081,699	2034-02-25	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,258,661	2036-09-23	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,507,255	2037-05-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ofatumumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,016,338	2036-12-20	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,035,848	2035-01-08	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,047,163	2034-02-07	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10,053,498	2035-11-20	Patent claims search

International Patents for ofatumumab

Country	Patent Number	Estimated Expiration
Serbia	54596
New Zealand	599516
South Korea	20120098872
Lithuania	3821912

Market Dynamics and Financial Trajectory for Ofatumumab

Last updated: February 20, 2026

Ofatumumab, a fully human monoclonal antibody targeting CD20, is approved for multiple sclerosis (MS) and certain hematologic conditions. Its market positioning and financial outlook depend on regulatory decisions, competitive landscape, and pipeline developments.

Market Overview

Approved Indications and Commercial Data

• Multiple Sclerosis (MS): Approved by the FDA and EMA for relapsing forms of MS in 2020.
• Chronic Lymphocytic Leukemia (CLL): Approved in the U.S. for CLL in combination with chlorambucil (2014).
• Pricing: Estimated annual treatment cost ranges from $70,000 to $100,000, depending on indication and dosing regimen.

Market Size

Indication	Estimated U.S. Market Size (2023)	Key Competitors	Market Share (as of 2023)
MS	$7 billion	Ocrelizumab, Rituximab, ofatumumab	10-12%
CLL	$4 billion	Obinutuzumab, Rituximab	20-25%

Source: EvaluatePharma [1], IQVIA [2]

Sales Performance

• Initial launch in MS yielded $150 million in 2021.
• Sales grew to approximately $250 million in 2022.
• First-half 2023 revenue: $130 million.

Market Dynamics

Competitive Landscape

• Ocrelizumab (Ocrevus): Dominates MS market, with ~50% share.
• Rituximab: Widely used off-label and in biosimilars, impacting ofatumumab's share.
• Obinutuzumab: Growing presence in CLL and follicular lymphoma.
• Emerging Therapies: S1P modulators and oral MS treatments are gaining ground.

Regulatory and Commercial Challenges

• Labeling Limitations: Approved for relapsing MS but not primary progressive MS, restricting market scope.
• Pricing and Reimbursement: High cost limits adoption; reimbursement policies influence market penetration.
• Market Penetration: Competition with established drugs reduces rapid uptake.

Pipeline and Future Approvals

• Data from ongoing trials on convenience (monthly subcutaneous dosing) could expand indications.
• Possible approval in primary progressive MS (PPMS) remains under investigation—wide industry interest.

Financial Trajectory

Revenue Forecasts

Year	Estimated Revenue	Assumptions	Sources
2023	$250 million	Steady growth, market penetration at 12%, stable pricing	Company reports [3]
2024	$300 million	Extended approval in PPMS, increased market penetration	Analyst estimates [4]
2025	$350 million	Possible pipeline approvals and new indications	Industry forecasts [5]

Cost Considerations

• Development Costs: R&D investments for new indications and formulations.
• Manufacturing: Scale-up costs for bioreactors and quality control.
• Marketing: Promotion amidst competitive landscape.

Profitability Outlook

• Margins depend on biosimilar competition in older indications.
• Pricing strategies and reimbursement policies influence profit margins.

Strategic Factors

• Manufacturing investments in biosimilar production to leverage global opportunities.
• Partnership potential with regional distributors for expanded reach.
• Pipeline development targeting broader MS and blood cancers.

Key Takeaways

• Ofatumumab's market is stabilized in relapsing MS and CLL with strong competition.
• Revenue growth relies on expanded indications, pipeline success, and market penetration.
• Competition, reimbursement policies, and pricing pressures present ongoing challenges.
• Future growth hinges on clinical advancements and regulatory approvals for broader indications.

FAQs

1. How does ofatumumab compare to ocrelizumab in MS treatment?
Ofatumumab is administered subcutaneously monthly, offering convenience over ocrelizumab’s intravenous infusions. Efficacy is comparable, but ocrelizumab currently holds a larger market share.

2. What are the main barriers to expanding ofatumumab’s market?
Limited approved indications restrict revenue; high treatment costs and established competition hamper rapid market penetration.

3. Are biosimilars a threat to ofatumumab’s profitability?
Yes. As patents expire, biosimilars targeting CD20 drugs could reduce prices and margins.

4. What is the potential for ofatumumab in primary progressive MS?
Ongoing trials may secure approval, opening a new market segment if successful.

5. How significant is pipeline development for future revenue?
Vital. New formulations, indications, and combination therapies can extend product lifecycle and improve financial outcomes.

References

1. EvaluatePharma. (2023). Oncology and immunology market analysis.
2. IQVIA. (2023). Global oncology insights.
3. GlaxoSmithKline. (2023). Financial reports.
4. Industry analyst estimates. (2023). Biotech market forecast.
5. Health Economics Review. (2022). Biologic drug pipeline outlook.

---

Note: All figures are estimates based on publicly available data and may vary with market changes.